December Update 2018

December Update 2018

Thanks to the successful financing round of CHF 10.25 million in May 2018, the InnoMedica team reached an important milestone with Talidox with the start of the clinical trial and made strategically relevant progress in clinical development and raw material…

November 2018: Start of the clinical trial with Talidox

November 2018: Start of the clinical trial with Talidox

Swissmedic has approved the clinical study phase I with Talidox. After production met all pharmaceutical standards, InnoMedica’s quality assurance released Talidox for clinical use. Last Monday, November 12, 2018, the first cancer patient was treated with Talidox at the Cantonal…

June 2018: Annual General Meeting 2018

June 2018: Annual General Meeting 2018

The Board of InnoMedica invites all shareholders to attend the Annual General Meeting 2018. The Annual General Meeting will be held on Tuesday, June 26th  2018 at 04:30 pm (doors open at 04:15 pm) in the Careum Auditorium – Pestalozzistrasse 11, 8032 Zürich. Shareholders…

June 2018: New capital of CHF 10.25 million

June 2018: New capital of CHF 10.25 million

The 2018 capital increase was closed on May 31 with subscriptions in the amount of CHF 10.25 million. As in previous financing rounds, we were able to substantially expand our shareholder base also this year and now count around 640…

March - May 2018: Capital increase with public offering

March – May 2018: Capital increase with public offering

Capital increase with public offering of 153,272 bearer shares / CHF 31,574,032 The subscription ends May 31st 2018. Share price is CHF 206 per new share (minimum 75 shares).   Visit us at an investor event in Bern, Zurich, Basel,…

Update December 2017

Thanks to the successful financing round of CHF 7.7 million in May 2017, the InnoMedica team has achieved significant progress with Talidox in recent months and further developed a new liposomal application in the field of neurodegenerative diseases into a…

June 2017: Annual general meeting 2017

The Board of InnoMedica invites all shareholders to attend the Annual General Meeting 2017. The Annual General Meeting will be held on Tuesday, June 20th  2017 at 04:30 pm (doors open at 04:15 pm) in the conference room of the OBC Suisse AG…

March-May 2017: Capital increase with public offering

March-May 2017: Capital increase with public offering

Join our oncology-project: Capital increase with public offer of 75,000 bearer shares / CHF 7,706,250 The subscription ends May 31, 2017. Share price is CHF 102.75 per new share (minimum 150 shares). Visit us at an investor event in Bern, Zurich or…

Fall term update 2016

Fall term update 2016

Thanks to the successful financing round of CHF 3.3 million in May 2016, the InnoMedica team was able to further advance the Talidox project in the last few months and to gain fundamental progress in the fields of preclinical, clinical…

Getting Talidox to the cancer patients

Getting Talidox to the cancer patients

InnoMedica has made a good start to the New Year and is getting Talidox at full speed into the clinics. InnoMedica and SAKK are ready for the registration of the clinical trial phase I: After acquiring the required financial funding…